id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12856 R48498 |
Thomas (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 | Urinary malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.40 [0.04;3.68] C excluded (control group) |
4/490 1/50 | 5 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12858 R48510 |
Thomas (Carbamazepine) (Controls unexposed, sick), 2021 | Urinary malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.46 [0.13;1.64] C | 4/490 6/340 | 10 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9678 R34455 |
Tomson (Carbamazepine), 2018 | Renal malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.93 [0.79;4.74] C | 12/1,957 8/2,514 | 20 | 1,957 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9643 R34310 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Urinary | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 1.83 [0.30;10.97] C | 3/685 2/833 | 5 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9652 R34352 |
Artama (Carbamazepine), 2005 | Urinary system | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 2.34 [0.21;25.81] C | 2/805 1/939 | 3 | 805 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.30 [0.60;2.80] | 38 | 3,937 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine; 3: Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications; 4: Carbamazepine;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 12856